NDASUBCUTANEOUSSOLUTION
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
SOMATULINE DEPOT (lanreotide acetate) by Ipsen is lanreotide, the active component of somatuline depot is an octapeptide analog of natural somatostatin. First approved in 2007.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMATULINE DEPOT is a somatostatin analog (lanreotide acetate) administered as a subcutaneous depot injection for the treatment of acromegaly and neuroendocrine tumors. It works by mimicking natural somatostatin to suppress growth hormone and other hormone secretion. The long-acting formulation allows for extended dosing intervals, improving patient convenience and compliance.
$53MPart D
LOE ApproachingProduct is approaching loss of exclusivity with moderate commercial volume (~5.4K Part D claims in 2023), indicating a consolidating team focused on defending market share against generics and competing somatostatin analogs.
Mechanism of Action
Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Started May 2009
115 enrolled
Carcinoid Syndrome
Career Relevance
Working on SOMATULINE DEPOT offers stable commercial experience in a niche, well-defined therapeutic area (endocrinology and oncology). However, approaching LOE means career growth is limited; roles emphasize defending market position, managing generic transition, and optimizing channel access rather than launching new indications.
Brand Manager
Worked on SOMATULINE DEPOT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.